Pyroptosis as a candidate therapeutic target for Alzheimer’s disease

Published on September 15, 2022

Imagine the brain as a bustling city, with each neuron representing a citizen. However, in the case of Alzheimer’s disease, this city experiences a devastating epidemic of cell death called pyroptosis. Pyroptosis is like a city-wide riot, triggered by inflammasomes and gasdermins. It’s a hot topic in the world of neurodegenerative diseases, and researchers are investigating its role in Alzheimer’s disease (AD). AD is characterized by the buildup of β-amyloid (Aβ) and hyperphosphorylated Tau, leading to inflammation and neural loss. Microglia, like the brain’s own police force, play a pivotal role in this chaos by undergoing pyroptosis and causing further inflammation. In this study, scientists delve into the pathogenesis of AD, focusing on pyroptosis and its potential as a therapeutic target. By understanding the underlying mechanisms of cell death and inflammation, researchers hope to pave the way for new medications targeting pyroptosis in AD patients.

Pyroptosis is a form of cell death mediated by inflammasomes and gasdermins, and the relevance of pyroptosis to neurodegenerative diseases is currently receiving increasing attention. Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disease that is closely associated with neuroinflammation. Its main pathological features include β-amyloid (Aβ) deposition, Tau protein hyperphosphorylation and neuronal loss. Aβ, tau-induced microglia pyroptosis and polarization leading to neuroinflammation play an important role in the pathogenesis of AD. Studying the pathogenesis and treatment of AD based on cellular pyroptosis has become a new direction in AD research. In this paper, we review the research progress of pyroptosis and will focus on the pathogenic roles of pyroptosis in AD and the role of targeted inhibition of inflammasome-dependent pyroptosis in AD treatment. These results deepen our understanding of the pathogenesis of AD and provide ideas for the development of new drugs based on the regulation of pyroptosis in AD patients.

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>